MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
GlaxoSmithKline plc (GSK)
Organization & Developments: GSK (GlaxoSmithKline)
*GlaxoSmithKline-GSK Center of Excellence for External Drug Discovery
Galapagos NV (NASDAQ: GLPG)*
Organization & Developments: Galapagos
Parents
Galapagos NV (NASDAQ: GLPG)*
Children
*Galapagos has developed a target discovery platform that provides novel starting points for drug and antibody therapies
*Thereby addressing the industry's need for innovative, disease-modifying medicines.
2015: Galapagos' drug is filgotinib, which is due to start phase three trials in rheumatoid arthritis and Crohn's disease next year
2015: Gilead Buys Into Galapagos Drug Filgotinib, Which AbbVie Ditched
2018: Galapagos: Continued Upside In 2018 - Galapagos (NASDAQ:GLPG)
2019: Behind Gilead's Big Move On Galapagos_seekingalpha.com
2019: Galapagos: Our Predictive Tools See Upside Despite Surge_seekingalpha.com
2020: Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients Brussels Stock Exchange:GLPG
2020: Galapagos Is A Buy Despite Setback In The U.S.
2022: Galapagos lays off 200 staff, drops kidney and fibrosis programs in renewed CAR-T push
2023: Galapagos: Navigating Uncharted CAR-T Waters With A Cash Compass_seekingalpha.com
2024: Galapagos Struggles To Carve A Path In A Crowded CAR-T Therapy Market
2024: Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond
2025: Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership
2025: Galapagos' Strategic Shift: Betting On CAR-T And A Fresh Start (Rating Upgrade)
Jumps
*Key People: Galapagos
Finance & Acquisitions: Galapagos